Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a Healthcare company (Biotechnology) with a market capitalization of $660M. The Maz Rating grades it against the other companies in its sector.
Nuvectis Pharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.20, Nuvectis Pharma, Inc. trades at 4.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -119.9%, return on invested capital of -41.2% and a free cash flow yield of -6.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 9.92. Over the past 52 weeks the share price ranged from $5.77 to $29.28, with a beta of -0.24.
Nuvectis Pharma, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Nuvectis Pharma, Inc. (NVCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 27.1% / 30% · Interest income / Revenue 97900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 27.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 97900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 27.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 97900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 99.7% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 97900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 99.9% / 33.33% · (Cash+Recv) / Total Assets 99.9% / 33.33% · Interest income / Revenue 97900000.0% / 5% | Fail |
No. As of September 2026, Nuvectis Pharma, Inc. (NVCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Nuvectis Pharma, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 97900000.0% of each dividend: Nuvectis Pharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.